| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10e4b1416c6e66e0ade5429212414964 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-225 |
| filingDate |
2017-07-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d079cfa501e097c3ec40e57275c2efa6 |
| publicationDate |
2017-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017222691-A |
| titleOfInvention |
Use of high-dose laquinimod to treat multiple sclerosis |
| abstract |
The present invention provides a method for treating a human patient suffering from multiple sclerosis (MS) or a human patient presenting with a clinically isolated syndrome (CIS). An oral dose of about 1.2 mg laquinimod or a pharmaceutically acceptable salt thereof is orally administered to a human patient suffering from multiple sclerosis or a human patient presenting with a clinically isolated syndrome. A method comprising administering. As well as for neuroprotection against human subjects, to increase time to disease progression confirmed in human patients, to increase time to confirmed recurrence, or to reduce brain atrophy An oral unit dosage pharmaceutical form of about 1.2 mg of laquinimod or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. [Selection figure] None |
| priorityDate |
2012-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |